课题基金 / 基金详情

EFALIZUMAB (RAPTIVA) COMBINED WITH SIROLIMUS IN TYPE 1 DIABETIC ISLET ALLOGRAFT

EFALIZUMAB (RAPTIVA) COMBINED WITH SIROLIMUS IN TYPE 1 DIABETIC ISLET ALLOGRAFT
EFALIZUMAB (RAPTIVA) 与西罗莫司联合用于 1 型糖尿病胰岛同种移植术
批准号:
7951730
负责人:
Bernhard Josef Hering
金额:
$1.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-12-01 至 2009-11-30

项目摘要

项目成果

Bernhard Josef Hering的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project aims to improve the applicability of islet transplantation for treatment of type 1 diabetes by utilizing novel immunosuppressive regimens centered on the use of adhesion molecule blockade with an anti-LFA-1 antibody and sirolimus maintenance with Anti-Thymocyte globulin induction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
  • 批准号:
    10622209
  • 项目类别:
  • 资助金额:
    $97.14万
  • 财政年份:
    2023
  • 负责人:
    Bernhard Josef Hering
  • 依托单位:
Deep Immune Profiling of Nonchimeric Tolerance of Transplants in Nonhuman Primates
  • 批准号:
    10353191
  • 项目类别:
  • 资助金额:
    $23.25万
  • 财政年份:
    2022
  • 负责人:
    Bernhard Josef Hering
  • 依托单位:
Deep Immune Profiling of Nonchimeric Tolerance of Transplants in Nonhuman Primates
  • 批准号:
    10612925
  • 项目类别:
  • 资助金额:
    $19.38万
  • 财政年份:
    2022
  • 负责人:
    Bernhard Josef Hering
  • 依托单位:
Alloantigen Delivery Via ECDI-Fixed Cells For Tolerance To Monkey Islet Grafts
  • 批准号:
    8518234
  • 项目类别:
  • 资助金额:
    $83.9万
  • 财政年份:
    2012
  • 负责人:
    Bernhard Josef Hering
  • 依托单位: